Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis

References

• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. doi:10.1016/S0140-6736(07)61128-3
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Camela E. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022;1–18. doi:10.1080/14712598.2022.2089020
   Web of Science ®Google Scholar
• Petit RG, Cano A, Ortiz A, et al. Psoriasis: from pathogenesis to pharmacological and nano-technological-based therapeutics. Int J Mol Sci. 2021;22(9):4983. doi:10.3390/ijms22094983
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi:10.1016/j.jaad.2016.07.064
   PubMed Web of Science ®Google Scholar
• Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge? Biomedicines. 2021;9(10):1482. doi:10.3390/biomedicines9101482
   PubMed Web of Science ®Google Scholar
• Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579. doi:10.3389/fimmu.2018.00579
   PubMed Web of Science ®Google Scholar
• Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):4347. doi:10.3390/ijms20184347
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023:1–17. doi:10.1080/14740338.2023.2173170
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023:1–16. doi:10.1080/14740338.2023.2173171
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498. doi:10.1111/jdv.16915
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281–317. doi:10.1111/jdv.16926
   PubMed Web of Science ®Google Scholar
• Dave R, Alkeswani A. An overview of biologics for psoriasis. J Drugs Dermatol. 2021;20(11):1246–1247. doi:10.36849/jdd.6040
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M. Towards personalized medicine in psoriasis: current progress. Psoriasis. 2022;12:231–250. doi:10.2147/PTT.S328460
   PubMed Web of Science ®Google Scholar
• Honma M, Hayashi K. Psoriasis: recent progress in molecular-targeted therapies. J Dermatol. 2021;48(6):761–777. doi:10.1111/1346-8138.15727
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;1–3. doi:10.1080/14712598.2022.2113872
   Web of Science ®Google Scholar
• Megna M, Potestio L, Camela E, Fabbrocini G, Ruggiero A. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;35:e15667. doi:10.1111/dth.15667
   PubMed Web of Science ®Google Scholar
• Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022:1–8. doi:10.1080/09546634.2022.2081655
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Cinelli E. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34:e15030. doi:10.1111/dth.15030
   PubMed Web of Science ®Google Scholar
• Marasca C, Fornaro L, Martora F, Picone V, Fabbrocini G, Megna M. Onset of vitiligo in a psoriasis patient on ixekizumab. Dermatol Ther. 2021;34(5):e15102. doi:10.1111/dth.15102
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M. Bimekizumab for the Treatment of psoriasis: a review of the current knowledge. Psoriasis. 2022;12:127–137. doi:10.2147/PTT.S367744
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Camela E, Potestio L, Fabbrocini G, Megna M. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(12):1445–1451. doi:10.1080/14740338.2022.2160447
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol. 2018;45(3):279–286. doi:10.1111/1346-8138.14096
   PubMed Web of Science ®Google Scholar
• Shivalkar S, Pingali MS, Verma A, et al. Outbreak of COVID-19: a detailed overview and its consequences. Adv Exp Med Biol. 2021;1353:23–45. doi:10.1007/978-3-030-85113-2_2
   PubMedGoogle Scholar
• Sharma A, Ahmad Farouk I, Lal SK. COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention. Viruses. 2021;13(2):202. doi:10.3390/v13020202
   PubMed Web of Science ®Google Scholar
• Marasca C, Annunziata MC, Camela E, et al. Teledermatology and Inflammatory skin conditions during COVID-19 era: new perspectives and applications. J Clin Med. 2022;11(6):1511. doi:10.3390/jcm11061511
   PubMed Web of Science ®Google Scholar
• De Lucia M, Potestio L, Costanzo L, Fabbrocini G, Gallo L. Scabies outbreak during COVID-19: an Italian experience. Int J Dermatol. 2021;60(10):1307–1308. doi:10.1111/ijd.15809
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Megna M, Fabbrocini G, Martora F. Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clin Exp Dermatol. 2022;47:1863–1864. doi:10.1111/ced.15286
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Fabbrocini G, Ruggiero A. Strategies adopted in a southern Italian referral centre to reduce Adalimumab discontinuation: comment on “Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa? Clin Exp Dermatol. 2022;47:1864–1865. doi:10.1111/ced.15291
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Nappa P, Megna M. Impact of the COVID-19 pandemic on hospital admissions of patients with rare diseases: an experience of a Southern Italy referral center. Int J Dermatol. 2022;61(7):e237–e238. doi:10.1111/ijd.16236
   PubMed Web of Science ®Google Scholar
• Hadj Hassine I. Covid-19 vaccines and variants of concern: a review. Rev Med Virol. 2022;32(4):e2313. doi:10.1002/rmv.2313
   PubMed Web of Science ®Google Scholar
• Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and moderna vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663–1669. doi:10.26355/eurrev_202102_24877
   PubMed Web of Science ®Google Scholar
• Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing. 2021;50(2):279–283. doi:10.1093/ageing/afaa274
   PubMed Web of Science ®Google Scholar
• Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12:714170. doi:10.3389/fimmu.2021.714170
   PubMed Web of Science ®Google Scholar
• Martora F, Picone V, Fabbrocini G, Marasca C. Hidradenitis suppurativa flares following COVID-19 vaccination: a case series. JAAD Case Rep. 2022;23:42–45. doi:10.1016/j.jdcr.2022.03.008
   PubMedGoogle Scholar
• Martora F, Picone V, Fornaro L, Fabbrocini G, Marasca C. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies? J Med Virol. 2022;94(4):1292–1293. doi:10.1002/jmv.27535
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: a case series. Dermatol Ther. 2022;35(2):e15225. doi:10.1111/dth.15225
   PubMed Web of Science ®Google Scholar
• Zagaria O, Villani A, Ruggiero A, Potestio L, Fabbrocini G, Gallo L. New-onset lichen planus arising after COVID-19 vaccination. Dermatol Ther. 2022;35(5):e15374. doi:10.1111/dth.15374
   PubMed Web of Science ®Google Scholar
• Ciechanowicz P, Dopytalska K, Mikucka-Wituszyńska A, et al. The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy. J Dermatolog Treat. 2022;33(3):1581–1584. doi:10.1080/09546634.2020.1861177
   PubMed Web of Science ®Google Scholar
• He M, Ferris LK, Gabriel N, Tadrous M, Hernandez I. COVID-19 and adherence to biologic therapies for psoriasis: an analysis of nationwide pharmacy claims data. J Manag Care Spec Pharm. 2022;28(11):1213–1218. doi:10.18553/jmcp.2022.28.11.1213
   PubMed Web of Science ®Google Scholar
• Ebrahimi A, Sayad B, Rahimi Z. COVID-19 and psoriasis: biologic treatment and challenges. J Dermatolog Treat. 2022;33(2):699–703. doi:10.1080/09546634.2020.1789051
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Marasca C, Fabbrocini G. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat. 2020;31(4):328–329. doi:10.1080/09546634.2020.1757605
   PubMed Web of Science ®Google Scholar
• Khosravi-Hafshejani T, Ghoreishi M, Vera Kellet C, Crawford RI, Martinka M, Dutz JP. Small plaque psoriasis re-visited: a type of psoriasis mediated by a type-I interferon pathway. Exp Dermatol. 2022;31(5):753–763. doi:10.1111/exd.14513
   PubMed Web of Science ®Google Scholar
• Catapano M, Vergnano M, Romano M, et al. IL-36 promotes systemic IFN-I responses in severe forms of psoriasis. J Invest Dermatol. 2020;140(4):816–826.e3. doi:10.1016/j.jid.2019.08.444
   PubMed Web of Science ®Google Scholar
• Piccolo V, Russo T, Mazzatenta C, et al. COVID vaccine-induced pustular psoriasis in patients with previous plaque type psoriasis. J Eur Acad Dermatol Venereol. 2022;36(5):e330–e332. doi:10.1111/jdv.17918
   PubMed Web of Science ®Google Scholar
• Ricardo JW, Lipner SR. Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine. JAAD Case Rep. 2021;17:18–20. doi:10.1016/j.jdcr.2021.09.009
   PubMedGoogle Scholar
• Romagnuolo M, Pontini P, Muratori S, Marzano AV, Moltrasio C. De novo annular pustular psoriasis following mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2022;36(8):e603–e605. doi:10.1111/jdv.18114
   PubMed Web of Science ®Google Scholar
• Lamberti A, Lora V, Graceffa D, Bonifati C, Cota C. Nail psoriasis: a rare mRNA COVID −19 vaccine reaction. J Eur Acad Dermatol Venereol. 2022;36. doi:10.1111/jdv.18255
   Google Scholar
• Elamin S, Hinds F, Tolland J. De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine. Clin Exp Dermatol. 2022;47(1):153–155. doi:10.1111/ced.14895
   PubMed Web of Science ®Google Scholar
• Frioui R, Chamli A, Zaouak A, et al. A case of new-onset acute generalized pustular psoriasis following Pfizer-BioNTech COVID-19 vaccine. Dermatol Ther. 2022;35(6):e15444. doi:10.1111/dth.15444
   PubMed Web of Science ®Google Scholar
• Durmaz I, Turkmen D, Altunisik N, Toplu SA. Exacerbations of generalized pustular psoriasis, palmoplantar psoriasis, and psoriasis vulgaris after mRNA COVID-19 vaccine: a report of three cases. Dermatol Ther. 2022;35(4):e15331. doi:10.1111/dth.15331
   PubMed Web of Science ®Google Scholar
• Pavia G, Gargiulo L, Spinelli F, et al. Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab. J Eur Acad Dermatol Venereol. 2022;36(7):e502–e505. doi:10.1111/jdv.18032
   PubMed Web of Science ®Google Scholar
• Krajewski PK, Matusiak Ł, Szepietowski JC. Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine. J Eur Acad Dermatol Venereol. 2021;35(10):e632–e634. doi:10.1111/jdv.17449
   PubMed Web of Science ®Google Scholar
• Perna D, Jones J, Schadt CR. Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine. JAAD Case Rep. 2021;17:1–3. doi:10.1016/j.jdcr.2021.08.035
   PubMedGoogle Scholar
• Shah H, Busquets AC. Psoriasis flares in patients with COVID-19 infection or vaccination: a case series. Cureus. 2022;14(6):e25987. doi:10.7759/cureus.25987
   PubMed Web of Science ®Google Scholar
• Sotiriou E, Tsentemeidou A, Bakirtzi K, Lallas A, Ioannides D, Vakirlis E. Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre. J Eur Acad Dermatol Venereol. 2021;35(12):e857–e859. doi:10.1111/jdv.17582
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Gallo L, Caiazzo G, Ruggiero A, Fabbrocini G. Reply to “Psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre. J Eur Acad Dermatol Venereol. 2022;36(1):e11–e13. doi:10.1111/jdv.17665
   PubMed Web of Science ®Google Scholar
• Koumaki D, Krueger-Krasagakis SE, Papadakis M, et al. Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre. J Eur Acad Dermatol Venereol. 2022;36(6):e411–e415. doi:10.1111/jdv.17965
   PubMed Web of Science ®Google Scholar
• Tsunoda K, Watabe D, Amano H. Exacerbation of psoriasis following vaccination with the Pfizer-BioNTech BTN162b2 mRNA COVID-19 vaccine during risankizumab treatment. J Dermatol. 2023;50(2):e79–e80. doi:10.1111/1346-8138.16505
   PubMedGoogle Scholar
• Ruggiero A, Potestio L, Battista T, Fabbrocini G, Megna M. Reply to “Nail psoriasis: a rare mRNA COVID-19 vaccine reaction”. J Eur Acad Dermatol Venereol. 2023;37(1):e41–e42. doi:10.1111/jdv.18537
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M. Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents. Expert Opin Biol Ther. 2021;21(11):1535–1537. doi:10.1080/14712598.2021.1965985
   PubMed Web of Science ®Google Scholar
• Musumeci ML, Caruso G, Trecarichi AC, Micali G. Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: a real life experience. Dermatol Ther. 2022;35(1):e15177. doi:10.1111/dth.15177
   PubMed Web of Science ®Google Scholar
• Damiani G, Allocco F, Malagoli P. COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers. Clin Exp Dermatol. 2021;46(6):1106–1108. doi:10.1111/ced.14631
   PubMed Web of Science ®Google Scholar
• Marovt M, Deželak P, Ekart R, Marko PB. Immune response to SARS-CoV-2 mRNA vaccine in patients with psoriasis treated with biologics. Clin Exp Dermatol. 2022;47(11):2041–2043. doi:10.1111/ced.15347
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Battista T, et al. Immune response to Covid-19 mRNA vaccination in psoriasis patients undergoing treatment with biologics. Clin Exp Dermatol. 2022;47:2310–2312. doi:10.1111/ced.15395
   PubMed Web of Science ®Google Scholar
• Cristaudo A, Graceffa D, Pimpinelli F, et al. Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs. J Eur Acad Dermatol Venereol. 2022;36(4):e266–e268. doi:10.1111/jdv.17861
   PubMed Web of Science ®Google Scholar
• Mercuri SR, Pacifico A, Malagoli P, et al. Heterologous Vs homologous primary and booster COVID-19 vaccination do not increase flare rate in patients with psoriasis and/or psoriatic arthritis: insights from a real-life, multicenter, case-control study. J Eur Acad Dermatol Venereol. 2023. doi:10.1111/jdv.18943
   PubMed Web of Science ®Google Scholar
• Napolitano M, Maffei M, Patruno C, et al. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. Dermatol Ther. 2021;34:e15120. doi:10.1111/dth.15120
   PubMed Web of Science ®Google Scholar
• Cantelli M, Martora F, Patruno C, Nappa P, Fabbrocini G, Napolitano M. Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report. Dermatol Ther. 2022;35(4):e15346. doi:10.1111/dth.15346
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Genco L, Martora F, Potestio L, Patruno C. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. J Eur Acad Dermatol Venereol. 2022;36(9):1497–1498. doi:10.1111/jdv.18137
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Martora F, Picone V, Morelli P, Patruno C. Role of aryl hydrocarbon receptor activation in inflammatory chronic skin diseases. Cells. 2021;10(12):3559. doi:10.3390/cells10123559
   PubMed Web of Science ®Google Scholar
• Martora F, Martora L, Fabbrocini G, Marasca C. A case of Pemphigus Vulgaris and Hidradenitis Suppurativa: may systemic steroids be considered in the standard management of Hidradenitis Suppurativa? Ski Appendage Disord. 2022;8(3):265–268. doi:10.1159/000521712
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, Marano L, Fabbrocini G, Marasca C. Paradoxical Hidradenitis Suppurativa during biologic therapy, an emerging challenge: a systematic review. Biomedicines. 2022;10(2):455. doi:10.3390/biomedicines10020455
   PubMed Web of Science ®Google Scholar
• Martora F, Megna M, Battista T, et al. Adalimumab, Ustekinumab, and Secukinumab in the management of Hidradenitis Suppurativa: a review of the real-life experience. Clin Cosmet Investig Dermatol. 2023;16:135–148. doi:10.2147/CCID.S391356
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-term efficacy and safety of Guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis. 2022;12:205–212. doi:10.2147/PTT.S372262
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690. doi:10.3390/ijms21051690
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. doi:10.1111/dth.15524
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;1–18. doi:10.1080/09546634.2022.2036674
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47:2280–2282. doi:10.1111/ced.15336
   PubMed Web of Science ®Google Scholar
• Elmas ÖF, Demirbaş A, Kutlu Ö, et al. Psoriasis and COVID-19: a narrative review with treatment considerations. Dermatol Ther. 2020;33(6):e13858. doi:10.1111/dth.13858
   PubMed Web of Science ®Google Scholar
• Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I. Biologic therapy for psoriasis during the COVID-19 outbreak: the choice is to weigh risks and benefits. Dermatol Ther. 2020;33(4):e13490. doi:10.1111/dth.13490
   PubMed Web of Science ®Google Scholar
• Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021;147(1):60–71. doi:10.1016/j.jaci.2020.10.007
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Fabbrocini G, et al. The role of teledermatology during the COVID-19 pandemic: a narrative review. Clin Cosmet Investig Dermatol. 2022;15:2785–2793. doi:10.2147/CCID.S377029
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Villani A, Tajani A, Fabbrocini G, Potestio L. Teledermatology: a useful tool also after COVID-19 era? J Cosmet Dermatol. 2022;21(6):2309–2310. doi:10.1111/jocd.14938
   PubMed Web of Science ®Google Scholar
• Shi CR, Nambudiri VE. Widespread psoriasis flare following influenza vaccination. Vaccine. 2017;35(36):4785–4786. doi:10.1016/j.vaccine.2017.06.067
   PubMed Web of Science ®Google Scholar
• Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial. Nat Med. 2021;27(2):270–278. doi:10.1038/s41591-020-01194-5
   PubMed Web of Science ®Google Scholar
• Farkas A, Tonel G, Nestle FO. Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells. Br J Dermatol. 2008;158(5):921–929. doi:10.1111/j.1365-2133.2008.08508.x
   PubMed Web of Science ®Google Scholar
• Takayama K, Satoh T, Hayashi M, Yokozeki H. Psoriatic skin lesions induced by BCG vaccination. Acta Derm Venereol. 2008;88(6):621–622. doi:10.2340/00015555-0496
   PubMed Web of Science ®Google Scholar
• Potestio L, Genco L, Villani A, et al. Reply to ‘Cutaneous adverse effects of the available COVID −19 vaccines in India: a questionnaire-based study’. J Eur Acad Dermatol Venereol. 2022;36. doi:10.1111/jdv.18341
   Web of Science ®Google Scholar
• Picone V, Fabbrocini G, Martora L, Martora F. A case of new-onset lichen planus after COVID-19 vaccination. Dermatol Ther. 2022;12(3):801–805. doi:10.1007/s13555-022-00689-y
   Web of Science ®Google Scholar
• Picone V, Martora F, Fabbrocini G, Marano L. “Covid arm”: abnormal side effect after Moderna COVID-19 vaccine. Dermatol Ther. 2022;35(1):e15197. doi:10.1111/dth.15197
   PubMed Web of Science ®Google Scholar
• Martora F, Villani A, Battista T, Fabbrocini G, Potestio L. COVID-19 vaccination and inflammatory skin diseases. J Cosmet Dermatol. 2023;22(1):32–33. doi:10.1111/jocd.15414
   PubMed Web of Science ®Google Scholar
• Potestio L, Villani A, Fabbrocini G, Martora F. Cutaneous reactions following booster dose of COVID-19 mRNA vaccination: what we should know? J Cosmet Dermatol. 2022;21:5339–5340. doi:10.1111/jocd.15331
   PubMed Web of Science ®Google Scholar
• Potestio L, Fabbrocini G, D’Agostino M, Piscitelli I, Martora F. Cutaneous reactions following COVID-19 vaccination: the evidence says “less fear”. J Cosmet Dermatol. 2023;22(1):28–29. doi:10.1111/jocd.15533
   PubMed Web of Science ®Google Scholar
• Gisondi P, Geat D, Bellinato F, Girolomoni G. Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis. Expert Opin Biol Ther. 2022;1–9. doi:10.1080/14712598.2022.2110467
   Web of Science ®Google Scholar
• Papp KA, Haraoui B, Kumar D, et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg. 2019;23(1):50–74. doi:10.1177/1203475418811335
   PubMed Web of Science ®Google Scholar
• Stingeni L, Bianchi L, Peris K, et al. SARS-CoV-2 vaccines and biological treatments: dermatological perspectives. Ital J Dermatol Venereol. 2021;156(2):118–120. doi:10.23736/S2784-8671.21.07055-9
   PubMedGoogle Scholar
• Martora F, Fabbrocini G, Nappa P, Megna M. Reply to ‘development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2’ by Solimani et al. J Eur Acad Dermatol Venereol. 2022;36(10):e750–e751. doi:10.1111/jdv.18302
   PubMed Web of Science ®Google Scholar